20 articles
Demethyleneberberine, derived from traditional Chinese medicine, significantly reduced lung scarring by targeting NLRP3 inflammasome and EMT in mice.
Structural biology uncovers the exact amino acid motif causing species-specific drug failures, enabling transgenic mouse models for better P2X7 drug testing.
Senescent cells drive cyst growth in ADPKD, and targeting them with senolytics or the aldose reductase inhibitor epalrestat delays disease progression.
A new veterinary sedative is contaminating the illegal fentanyl supply, posing novel overdose risks that standard treatments may not reverse.
A pilot study finds one 30-minute PAPIMI electromagnetic field session significantly reduced pain scores and raised parasympathetic HRV markers in chronic musculoskeletal pain patients.
Breakthrough therapy targeting B cells demonstrates significant improvement in lupus symptoms with sustained benefits over one year.
Systematic uric acid monitoring and treatment achieved 64% better remission rates than waiting for symptoms to guide therapy.
Updated EULAR recommendations provide comprehensive management strategies for this complex autoimmune condition affecting multiple organs.
Researchers tested whether eosinophil β1 integrin activation in blood could track disease activity, potentially sparing patients repeat invasive procedures.
Breakthrough treatments targeting specific immune pathways show promise for reducing steroid dependence in EGPA patients.
New research reveals B cells in brain membranes play crucial roles in neural protection, aging, and neurodegenerative diseases.
NYU study reveals how targeted immune therapy transforms inflammatory responses in rheumatoid arthritis treatment.
Scientists discover unique immune peptide patterns in Behçet's disease patients that trigger harmful inflammation responses.
Phase 2 trial tests novel therapy for patients who failed standard biologics and JAK inhibitors in 145-person study.
New study reveals specific immune and microbiome signatures that could predict depression in lupus patients with 85% accuracy.
GlaxoSmithKline tests a novel NS5B inhibitor across four dose groups in chronic HCV patients, evaluating safety and short-term antiviral activity.
Genetic variants of Epstein-Barr virus influence how well MS patients respond to interferon therapy, enabling personalized treatment.
Scientists reveal how a measles antiviral also blocks Nipah virus and use structural insights to engineer more potent next-generation inhibitors.
New study shows preventive treatment can stop autoimmune arthritis before it starts in vulnerable populations.
Mice lacking the PERP apoptosis gene develop faulty thymic immune screening, accumulating self-reactive T-cells that trigger arthritis as they age.
